Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic genomics platform.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic genomics platform.